Insilico Medicine has received the first clinical milestone payment of $10 million for XL309 (previously known as ISM3091) from Exelixis. (IMAGE)

InSilico Medicine

Insilico Medicine has received the first clinical milestone payment of $10 million for XL309 (previously known as ISM3091) from Exelixis.

Caption

XL309 is a selective, orally bioavailable small molecule USP1 inhibitor, discovered by Insilico with the support of its proprietary AI platform and out-licensed to Exelixis in 2023. 

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.